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Abstract: Sphingolipids (SL) are structurally diverse lipids that are defined by the presence of a long
chain base (LCB) backbone. Typically, LCBs contain a single Δ4E DB (mostly d18:1), whereas the dienic
LCB sphingadienine (d18:2) contains a second DB at Δ14Z position. The enzyme introducing the Δ14Z
DB is unknown. We analyzed the LCB plasma profile in a gender-, age-, and BMI-matched subgroup of
the CoLaus cohort (n = 658). Sphingadienine levels showed a significant association with gender, being
in average 30% higher in females. A genome-wide association study (GWAS) revealed variants in the
fatty-acid desaturase 3 (FADS3) gene to be significantly associated with the plasma d18:2/d18:1 ratio
(p = -log 7.9). Metabolic labeling assays, FADS3 overexpression and knockdown approaches, as well as
plasma LCB profiling in FADS3-deficient mice confirmed that FADS3 is a bona-fide LCB desaturase and
required for the introduction of the Δ14Z double bound. Moreover, we showed that FADS3 is required for
the conversion of the atypical cytotoxic 1-deoxysphinganine (1-deoxySA, m18:0) to 1-deoxysphingosine
(1-deoxySO, m18:1). HEK293 cells overexpressing FADS3, were more resistant to m18:0 toxicity than
WT cells. In summary, using a combination of metabolic profiling and GWAS, we identified FADS3 to be
essential for forming Δ14Z DB containing LCBs, such as d18:2 and m18:1. Our results unravel FADS3 as
a Δ14Z LCB desaturase, thereby disclosing the last missing enzyme of the SL de novo synthesis pathway.
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ABSTRACT 
Sphingolipids (SL) are structurally diverse lipids 
that are defined by the presence of a long chain 
base (LCB) backbone. Typically, LCBs contain a 
single Δ4E DB (mostly d18:1), whereas the 
dienic LCB sphingadienine (d18:2) contains a 
second DB at Δ14Z position. The enzyme 
introducing the Δ14Z DB is unknown. We 
analyzed the LCB plasma profile in a gender-, 
age-, and BMI-matched subgroup of the CoLaus 
cohort (n = 658). Sphingadienine levels showed a 
significant association with gender, being in 
average ~30% higher in females. A genome-wide 
association study (GWAS) revealed variants in 
the fatty-acid desaturase 3 (FADS3) gene to be 
significantly associated with the plasma 
d18:2/d18:1 ratio (p=-log 7.9). Metabolic 
labeling assays, FADS3 overexpression and 
knockdown approaches, as well as plasma LCB 
profiling in FADS3-deficient mice confirmed that 
FADS3 is a bona-fide LCB desaturase and 
required for the introduction of the Δ14Z double 
bound. Moreover, we showed that FADS3 is 
required for the conversion of the atypical 
cytotoxic 1-deoxysphinganine (1-deoxySA, 
m18:0) to 1-deoxysphingosine (1-deoxySO, 
m18:1). HEK293 cells overexpressing FADS3, 
were more resistant to m18:0 toxicity than WT 
cells.  In summary, using a combination of 
metabolic profiling and GWAS, we identified 
FADS3 to be essential for forming Δ14Z DB 
containing LCBs, such as d18:2 and m18:1. Our 
results unravel FADS3 as a Δ14Z LCB 
desaturase, thereby disclosing the last missing 
enzyme of the SL de novo synthesis pathway.  
Introduction 
Sphingolipids (SLs) are a diverse class of lipids 
that share a long-chain base (LCB) backbone as a 
common structural element. Forming a LCB is 
the first and rate-limiting reaction in the de-novo 
synthesis of SL (Fig S1). During SL synthesis, 
LCBs are usually N-acylated to a fatty acid (FA) 
of variable length (C16-C26) forming ceramides 
and conjugated to variable head group structures 
forming complex SLs. LCBs are synthesized at 
the endoplasmic reticulum by the enzyme serine-
palmitoyltransferase (SPT). The most abundant 
LCB in mammals is the 18-carbon dihydroxy-
amino-alkane sphingosine (d18:1) that is formed 
by the conjugation of L-serine with palmitoyl-
CoA. SPT, however, can metabolize a variety of 
other acyl-CoA in the range of C14-C18 and use 
alanine and glycine as alternative substrates. This 
forms a broad variety of LCBs, which differ by 
structure, function and metabolism (1). 
1-DeoxySLs are atypical SLs, which are 
generated from alanine instead of serine and 
involved in a variety of pathological conditions 
including the rare hereditary sensory neuropathy 
type 1 (HSAN1) (2). Typically, LCBs present 
with a canonical Δ4E double bond (DB). 
However, the -dienic sphingoid base 
sphingadienine (d18:2) that is formed 
downstream of sphingosine (d18:1) has an 
additional DB at Δ14Z position (3,4). Recently, 
we reported that 1-deoxySO (m18:1) contains a 
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Δ14Z DB but lacks the canonical DB at Δ4E 
position (5). Whereas the Δ4E DB is introduced 
by the ceramide desaturase 1 (DEGS1), the 
enzyme responsible for the introduction of the 
Δ14Z DB is not known. Here we identified fatty-
acid desaturase type 3 (FADS3) as a bona fide 
sphingoid base desaturase introducing a DB in 
Δ14Z position and therefore responsible for 
converting d18:1 into d18:2 and 1-deoxySA 
(m18:0) into 1-deoxySO (m18:1). 
Results 
Human plasma contains different SL 
classes, of which the most abundant are 
Sphingomyelins (SM), HexosylCeramides 
(HexCer) and Ceramides (Cer). These classes are 
formed on a variety of LCB backbone structures 
and variations in their LCB composition are 
associated with different pathological conditions 
(6-8). Differences in the LCB profile predicts the 
risk for future diabetes type 2 (T2DM) 
independent from classical risk factor such as 
BMI and blood glucose (9).  Males and females 
have different risk profiles for T2DM. In men, 
T2DM is more frequently diagnosed at lower age 
and BMI whereas obesity is more common in 
women. We therefore compared the LCB profile 
in an age and BMI matched subgroup of female 
and male participants of the CoLaus cohort 
(N=329 each). LDL cholesterol, triglycerides and 
fasting glucose was not different between groups 
(Table 1) whereas total and HDL cholesterol was 
higher and waist to hip ratio lower in females (p=-
log 49.4). In plasma and tissue, the majority of 
LCBs is N-acylated and conjugated to variable 
head groups. Non-conjugated LCBs in plasma are 
minor and less than 1% of the total. The 
combination of a variable LCB with a variable 
FAs frequently results in the formation of 
isomeric structures (e.g. d18:1/24:0 vs 
d18:0/24:1) which interfere with the LCB 
analysis by LC-MS. To avoid interferences with 
the N-acyl chain, we subjected the extracted 
lipids to a sequential acid/base hydrolysis (10) to 
remove the conjugated FA and head groups. Here, 
we therefore reported total LCB concentrations 
without considering previously conjugated N-
acyl and head group structures.  
The LCB profiling revealed d18:1 as the 
most abundant LCB in plasma (57%) followed by 
d18:2 (21%), d16:1 (5%) and d17:1 (4.2%). The 
remaining LCB species were less than 5% in total 
(Fig 1A). A significant gender differences were 
seen for d18:2 (p= -log 32.3) followed by d17:1 
(p=-log 15.5) and d16:1 (p=-log 11.6) LCBs (Fig 
1B). In average, d18:2 was about 30% higher in 
females, whereas its precursor d18:1 was only 
10% increased. This indicates that the d18:1 to 
d18:2 conversion differs between genders. 
However, the enzyme responsible for this 
conversion was not known.  
To identify the responsible Δ14Z 
desaturase, we used genome wide SNP data, 
which were available for all European individuals 
of the cohort (11). As the enzyme converts d18:1 
into d18:2, we hypothesized that genetic 
variations in the desaturase gene will be reflected 
by changes in the d18:1 to d18:2 ratio. We 
therefore used this ratio as a metabolic outcome 
trait for a GWAS on 1100 participants of the 
CoLaus cohort of whom the LCB profile was 
already available from an earlier study (9).  The 
analysis revealed a group of adjacent SNPs, 
showing a significant association with the 
d18:1/d18:2 ratio. The strongest association was 
seen for SNP rs174455 (p= -log 7.93) that is 
located in an intronic region of the fatty acid 
desaturase 3 (FADS3) gene on chromosome 
11q12.2-13.1 (Fig 1D). The same region clusters 
two other desaturases, FADS1 and FADS2, 
which metabolize polyunsaturated fatty acids 
(PUFA) (12). In contrast, the function of FADS3 
was still elusive. The FADS3 gene spans 17.9 kb 
of genomic DNA and has the same structure as 
FADS1 and FADS2 consisting of 12 exons and 
11 introns. On protein level, FADS3 is 52% and 
62% homologous to FADS1 and FADS2, 
respectively.  
To test whether FADS3 is a Δ14Z LCB 
desaturase, we expressed the mouse and human 
FADS3 cDNA in HEK293 cells. Endogenous 
d18:2 levels in HEK293 cells were low, 
indicating a low activity of the putative Δ14Z 
desaturase.  For comparison, we also expressed 
the cDNA of mFADS1 and mFADS2. Expression 
levels were comparable for all constructs (Fig 
2A). Immune fluorescence microscopy showed 
an intracellular colocalisation of FADS3 with 
calnexin, indicating that FADS3 is an ER protein 
(Fig 2B).  
Enzyme activity was tested in human and 
mouse FADS3 expressing cells supplemented 
either with isotope labelled (d7)d18:0 or 
(d3)m18:0. The free LCBs were absorbed by the 
cells (13) and metabolized to (d7)ceramide and 
downstream products such as (d7)SM and 
(d7)HexCer (Fig S2A). After 48 hours, the lipids 
were extracted, hydrolyzed and the LCB profile 
analyzed by LC-MS. In both, mFADS3 and 






















































increase in d18:2 (Fig 2C, S2B) which was not 
seen in mFADS1 or mFADS2 expressing cells. In 
addition, FADS3 expressing cells showed an 
increased conversion of m18:0 into m18:1, 
indicating that the Δ14Z DB in 1-deoxySO is also 
formed by FADS3 (Fig 2D, S2C). To test whether 
FADS3 acts on N-acylated or free LCB, we 
treated cells with Fumonisin B1 (FB1). FB1 
blocks Ceramide Synthase (CerS) and therefore 
the N-acylation of LCBs. In the presence of FB1, 
the conversion was about 70% reduced, but a 
significant amount of  (d7)d18:1 was still 
converted into (d7)d18:2. This was confirmed in 
vitro, by adding either the free LCB (d7)d18:1 or 
the N-acylated d18:1/6:0 to cell free extract of 
FADS3 expressing HEK cells. Both, the free and 
the N-acylated LCBs were effectively converted 
into their dienic forms (Fig 2F), indicating that 
FADS3 is capable to metabolize both, free and N-
acylated LCBs.    
For further confirmation, we performed 
the reverse experiments by knocking down 
endogenous FADS3 in HeLa cells, which had a 
higher endogenous FADS3 expression than 
HEK293 cells. Transfection with FADS3 siRNA 
(siFADS3) abolished FADS3 expression almost 
completely compared to cells transfected with 
control siRNA (siSCR) (Fig 3A). LCB profiling 
revealed that, almost no isotope labelled 
(d7)d18:2 was formed in absence of FADS3, 
whereas in siSCR treated cells a significant 
conversion of (d7)d18:0 into (d7)d18:1 and 
finally into (d7)d18:2 was observed (Fig 3B). 
Similarly, the conversion of isotope labelled 
(d3)m18:0 into (d3)m18:1 was mostly abolished 
in siFADS3 treated cells (Fig 3C, S4).  
Finally, we analyzed the LCB profile in 
plasma of FADS3 deficient mice (14). No d18:2 
was detected in plasma of FADS -/- mice whereas 
FADS +/- mice had about 50% of the wildtype 
levels (Fig 3D).   
To see whether the Δ14Z DB has a 
biological relevance, we cultured WT and 
FADS3 overexpressing cells with increasing 
amounts of m18:0 and quantified the number of 
surviving cells after 48 hours. Hek293 cells 
overexpressing FADS3 were significantly more 
resistant to m18:0 toxicity than WT cells (Fig 3F).  
As d18:2 plasma levels were higher in 
females, we compared the FADS3 tissue 
expression between males and females using the 
public gene expression data from the GTEx portal 
(https://gtexportal.org). Overall, the highest 
FADS3 expression was seen for peripheral nerve, 
aorta and adipose tissue. The majority of tissues 
showed higher FADS3 expression in females. 
The most pronounced difference was seen for 
adipose tissues with 194.6 transcripts per million 
(TPM) in females vs 166.7 TPM in males.  
 
Discussion 
Sphingadienine (d18:2) is an atypical 
sphingoid base which contains two DBs,  a Δ4E 
and a Δ14Z (3,15). Whereas the Δ4E DB is 
introduced by DEGS1 during SL de-novo 
synthesis, the enzyme introducing the Δ14Z DB 
was not known. However, in a gender, age and 
BMI matched cohort, we identified d18:2 as the 
second most abundant LCB (Fig 1A) and 
significantly higher in females than in males. This 
confirms data from two recent epidemiologic 
studies, which also report gender specific 
difference in d18:2 based SL (16,17).  
Although, d18:2 was first described in the 
late 60’s (3), the responsible enzyme forming the 
Δ14Z double was not known. Based on genetic 
association studies in combination with in vivo 
and in vitro experiments, we identified FADS3 as 
a bona-fide delta Δ14Z long chain base 
desaturase. Data from the GTEx database 
revealed generally higher FADS3 expression in 
females for many tissues, including peripheral 
nerve and adipose tissue but also liver, kidney and 
muscle. Higher FADS3 expression was also 
reported for female mice (18) and might explain 
the gender specific differences in d18:2 plasma 
levels.  
Although, human FADS3 was first 
cloned in 2000 (19), its function remained 
elusive. FADS3 is composed of an N-terminal 
cytochrome b5-like domain and three histidine 
motifs at the C-terminal ends which is 
characteristic for membrane-bound front end 
desaturases (20). In vitro studies indicated that 
FADS3 is specific for trans-vaccenic acid (VA; 
trans11-18:1), catalyzing the synthesis of a 
trans11,cis13-linoleic acid isomer (Δ13 
desaturation) (21). Interestingly, an earlier 
GWAS on genetic determinants of circulating 
sphingolipids found FADS3 to be strongly 
associated with SM species containing mono-
unsaturated N-acyl chains (22). As d18:1 based 
SLs with unsaturated acyl chains (e.g. SM 
d18:1/24:1) are isobaric to SLs with a saturated 
fatty acids formed on d18:2 backbone (e.g. SM 
d18:2/24:0), these associations could also refer to 
–dienic SM species (Fig S3, S5).  
  FADS3 localizes to human chromosome 
11q13 (23) which is known as a cancer hotspot 






















































together with FADS1 and FADS2 which were 
identified previously as delta-5 and delta-6 
desaturases. FADS3 mRNA expression responds 
inversely to FADS1 and FADS2 expression 
levels. In FADS2 deficient mice, FADS3 
expression increased 3-fold (25) and reducing 
FADS1 and FADS2 expression by DHA and 
arachidonic acid (ARA) increases expression of 
FADS3 (26). FADS3 is spliced yielding to 
alternative transcripts, which are conserved in 
several mammalian and avian species (18,27). 
However, it is not yet clear whether these 
alternative transcripts are catalytically active. 
Little is known about the function of 
d18:2 based SLs. Previously, plasma levels of 
d18:2 SLs were inversely associated with the 
incidence for cardiovascular events (8), the body 
mass index and the HOMA index (28). It serves 
as a backbone for complex sphingolipids (Fig 1C) 
and forms -dienic LCB phosphates (SAdienine-
1P) (29). Free SAdienes and synthetic analogues 
exhibit cytotoxic and anti-proliferative effects in 
cancer and non-cancer cells (30,31) and were 
associated with the inhibition of colon 
tumorigenesis in mouse models (32,33). 
Mitochondrial and cellular pools of d18:2 based 
ceramides were elevated in embryonic fibroblasts 
derived from double knockout BAX-BAK mice 
and a mouse derived immortalized iBMK cell line 
(34). It is noteworthy that the Δ14 DB in d18:2 is 
in cis conformation, introducing a kink into the 
otherwise straight LCB structure. This might 
affect the lateral assembly of d18:2 based SLs in 
biological membranes and could interfere with 
membrane nano-domain formation and receptor 
clustering. In first reports, FADS3 KO mice 
showed no overt phenotype (14). No significant 
differences in survival, fertility or growth rate 
were seen. However, FADS3 KO mice were not 
yet tested under challenged metabolic conditions 
such as high fat diet.  Genetic variants of FADS3 
are associated with familial combined 
hyperlipidemia in the Mexican population (35) 
and the FADS3 SNP rs174455 was negatively 
associated with DHA levels in red blood cell 
phospholipids (36).  
1-DeoxySLs are an atypical class of toxic 
sphingolipids associated with the rare inherited 
neuropathy HSAN1 (37) and macular 
telangiectasia type 2 (38).  In contrast to canonical 
LCBs m18:1 contains only a single DB in Δ14Z 
position but lacks the Δ4E DB (5). Here we 
showed, that FADS3 is also responsible for the 
conversion of m18:0 into m18:1 (Fig 2D, 3C, S2 
and S4).  In addition, we showed, that FADS3 
expressing cells were more resistant to m18:0 
toxicity than WT cells (Fig 3E). This supports 
recent reports, indicating that m18:0 based 1-
deoxySL species are more associated with toxic 
effects than their unsaturated forms (39). In that 
respect, FADS3 might contribute to a 
physiological detoxification of 1-deoxySLs.  
It is not fully clear yet, whether FADS3 
activity is specific for N-acylated LCBs or 
whether it can also metabolize the free form. 
After blocking N-acylation with FB1, we still 
observed a conversion of (d7)d18:1 into 
(d7)d18:2, albeit at reduced levels (Fig 2D).  Also 
in-vitro assays showed, that FADS3 is capable in 
converting both, the N-acylated and the fee LCB. 
However, as free LCBs are typically minor, the 
conversion of free LCBs is likely of limited 
biological relevance.  
We recently reported that, DEGS1 
deficiency causes leukodystrophy and peripheral 
hypomyelination. Which was associated with a 
pathologically increased formation of saturated 
dihydroSL species (13) and the formation of an 
atypical monounsaturated d18:1 isomer. Further 
analysis showed that this isomer contained a 
Δ14Z DB but lacked the canonical Δ4E DB. This 
suggests that FADS3 can also metabolize 
saturated d18:0 although the atypical d18:1 
(Δ14Z) isomer was yet only detected under 
conditions with reduced DEGS1 activity.   
In conclusion, we identified FADS3 as a 
Δ14Z LCB desaturase introducing a Δ14Z DB 
into d18:1, and m18:0 based SLs and likely also 
other LCB substrates. This lights up the last 
obscure step in the SL de novo synthesis 
pathways, as the enzyme that forms d18:2 was not 
yet identified. The activity of FADS3 seems to be 
higher in females and relates to gender specific 
differences in the plasma sphingolipidome. In 
addition, we propose that FADS3 could be 
involved in the detoxification of 1-deoxySLs. 
However, further studies are required to 
understand role of FADS3 under physiological 
and pathophysiological conditions.  
 
Experimental procedures 
Approvals The Colaus study was 
conducted according to the principles expressed 
in the Declaration of Helsinki and approved by 
the Institutional Ethics Committee of the 
University of Lausanne.  
Animal studies were approved by the 
Cornell University Institutional Animal Care and 






















































Human samples and genome-wide 
association scan.  Two subgroups of age- and 
BMI-matched females and males (N=329 each) 
were selected from the CoLaus cohort (9,40). 
Genotyping and imputation of the cohort was 
described previously (41). Briefly, individuals 
with genotyping inconsistencies, or genotyping 
efficiency below 90%, were removed.  SNPs with 
genotyping efficiency below 70%, or Hardy--
Weinberg p-values smaller than 1E-7, were 
removed. Duplicate individuals, and first and 
second degree relatives, were identified by 
computing genomic identity-by-descent 
coefficients, using PLINK (42). Imputation was 
performed using the method of Marchini et al. 
(43), using IMPUTE version 0.2.0, CEU 
haplotypes and fine scale recombination map 
from HapMap release 21. Given the non-
Gaussian distribution of the examined LCBs, 
inverse normal quantile transformation was 
applied, regressing out age, sex and the first four 
ancestry principal components. The residual trait 
has been rescaled to have zero mean and unit 
variance. Linear regression analysis has been 
performed for 2’557’249 imputed genetic 
markers as explanatory variables. The 
probabilistic genotypes were converted to allele 
dosages.  
Cells and cell culture. HEK293 and HeLa 
cells (American Type Culture Collection) were 
cultured in Dulbecco′s Modified Eagle′s Medium 
(DMEM, ThermoFisher Scientific) with 10% 
FBS and 1% pen/strep (37°C in 5% CO2). 
Transfection was done using Lipofectamin 3000 
(ThermoFisher Scientific). Transfected cells were 
cultured under Blasticidin (ThermoFisher 
Scientific) for selection. hFADS3 and control 
siRNA was obtained from Origene and 
transfected with RNAiMAX (ThermoFisher 
Scientific) according to the manufacturer’s 
protocol.  
Immunohistochemistry HeLa cells were 
transfected and grown for 24h on 15-mm 
coverslips, fixed in 4% paraformaldehyde (30 
min, RT) and washed in PBS. Cells were blocked 
for 2h in PBS, 5% BSA, 1% NGS and 0.25% Tx-
100) and incubated with the primary antibodies 
overnight, anti-Calnexin antibody (Sigma, 
C4731) and anti-V5 antibody (BIORAD 
MCA1360) were used. Secondary antibodies 
(1:1000, Jackson ImmunoResearch) and DAPI 
(Invitrogen) was added for 4 hours. Cells were 
mounted on glass slides with ProLong Diamond 
Antifade Mountant (Thermo Fisher Scientific). 
Pictures were acquired on a confocal laser 
scanning microscope (Leica SP8; Leica 
Microsystems, Wetzlar, Germany, HC PL APO 
CS2 63x N.A. 1.4 oil) at  90.4nm*90.4nm*300nm 
(x*y*z) resolution and analyzed using Fiji image 
processing package (44). 
Protein isolation and Western blots were 
carried out as described elsewhere (13).  
Cloning FADS1 (NM_013402.4), 
FADS2 (NM_004265.3) and FADS3 
(XM_011545023.2) were amplified from a 
commercially available cDNA library using the 
following primers:  
FADS1 Forward: caccatgggaacgcgcgctgcgagg 
FADS1 Reverse: ttggtgaagataggcatctagccag 
FADS2 Forward: caccatggggaagggagggaaccag 
FADS2 Reverse: tttgtgaaggtaggcgtccag 
FADS3 Forward: caccatgggcggcgtcggggagcc 
FADS3 Reverse: ctgatggaggtaggcgtccagatg 
The PCR product was cloned into the pcDNA3.1 
V5-His-TOPO vector (ThermoFisher Scientific) 
and verified using Sanger sequencing. Myc-DDK 
tagged mouse FADS1-3 plasmids was 
commercially available (Origene).  
Lipidomics analysis was performed as 
described previously (13,45) using the internal 
standards (100 pmol/ml, Avanti Polar Lipids): 
(d5) 1-desoxymethylsphinganine (m17:0), 
dihydroceramide (d18:0:12:0), ceramide 
(d18:1/12:0), (d18:1/12:0), 1-
deoxydihydroceramide (m18:0/12:0), 1-
deoxyceramide (m18:0/12:0), glucosylceramide 
(d18:1/8:0) and sphingomyelin (d18:1/12:0).  
The plasma LCB profile was analyzed as 
described previously (10). For quantification (d5) 
1-desoxymethylSA (m17:0) was used as internal 
standard (Avanti Polar Lipids).  
Metabolic labelling assay 250,000 Cells 
were seeded and cultured in 6-well plates to 70%–
80% confluence. New medium containing isotope 
labelled (d3)m18:0, (d7)d18:0 or (d7)d18:1 
(Avanti Polar Lipids) was added. After 24 or 48 
hours, cells were harvested, counted (Beckman 
Coulter Vi-Cell XR), pelleted (600 g at 4°C) and 
stored at −20°C.  
Activity assay. FADS3 cell were lysed by 
sonication and the homogenate centrifuged at 
13000g for 5 minutes. For each condition 100 µg 
lysate in  100 µl PBS + 1mM NAD+ were 
incubate with 500 pmol (d7)d18:1 or d18:1/6:0 
for 5min. The products were measured by LC-
MS.  
Statistical analysis was performed using 
GraphPad Prism 8. A p-value of less than 0.05 
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     female   male       
     mean SD   mean SD   
fold 
diff -log(p) 
 n  329   329     
 age   59.77 9.07   58.31 10.52   1.02 1.24 
 BMI   28.61 5.03   27.82 4.28   1.03 1.50 
 waist/hip ratio   0.86 0.07   0.94 0.06   0.91 49.39 
 Chol (total)   5.94 1.09   5.63 0.94   1.06 4.08 
 HDL   1.66 0.40   1.38 0.31   1.20 21.24 
 LDL   3.59 0.95   3.51 0.82   1.02 0.66 
 Trig   1.51 0.70   1.63 0.84   0.93 1.37 
 Glu   6.02 1.67   6.14 1.79   0.98 0.43 
  C16SO d16:1 19.63 5.73   16.58 5.21   1.18 11.58 
  C16SA d16:0 0.51 0.20   0.44 0.18   1.14 4.65 
  C17SO d17:1 9.52 2.63   7.91 2.28   1.20 15.45 
  C18PhytoSO t18:0 0.15 0.05   0.14 0.04   1.02 0.47 
  C18SO d18:1 97.23 19.15   88.32 16.54   1.10 9.45 
  C18SA d18:0 3.51 1.08   3.12 1.00   1.12 5.48 
  C18SAdienine d18:2 35.05 7.80   28.01 6.33   1.25 32.26 
  C19SO d19:1 2.45 0.96   2.16 0.91   1.14 4.12 
  C20SO d20:1 0.20 0.06   0.19 0.05   1.03 0.57 
  C20SA d20:0 0.02 0.01   0.02 0.01   1.02 0.28 
 1-deoxySO m18:1 0.15 0.08   0.17 0.09   0.85 4.10 
 1-deoxySA m18:0 0.08 0.04   0.09 0.04   0.95 0.85 
 



























































Fig 1. LCB profiling and genetic associations.  
A-B Long chain base profile in human plasma. A Relative distribution of the most abundant LCBs in 
human plasma. B Differences in the concentration of the major plasma LCBs between females (F) and 
males (M) C Relative distribution of the LCB species d18:0, d18:1 and d18:2 in Ceramide (Cer), HexCer 
and SM in human plasma. The LCBs reflect the sum of Cer (C16:0, C18:0, C20:0, C22:0, C24:0 and 
C24:1), SM (C16:0, C18:0, C20:0, C22:0, C24:0 and C24:1) and HexCer (C16:0, C22:0, C24:0 and 
C24:1) and. D Manhattan plot of the GWAS revealed SNP rs174455 on Chromosome 11 to be 

























































Fig 2. FADS3 mediates the Δ14 LCB desaturation in mammalian cells.  
A Western blot of HEK293 cells stably expressing mouse (m)FADS1-3 (Myc-DDK) and human 
(h)FADS1-3 (V5) B Intracellular localization of hFADS3-V5 (red) overlaps with the ER marker 






















































base profiling of HEK293 cells supplemented with isotope labelled sphingoid bases. C Cells stably 
expressing mFADS1-3 and hFADS3 cultured for 48 hours with isotope-labeled (d7)d18:0. The levels 
of (d7)d18:2 was significantly elevated in mFADS3 and hFADS3 overexpressing cells but not altered 
in mFADS1 and mFADS2 cells. D FADS1-3 expressing HEK293 cells supplemented with isotope 
labelled (d3)m18:0 for 48h. (d3)m18:1 levels were higher in FADS3 expressing cells compared to WT, 
mFADS1 and mFADS2 cells. E HEK293 cells supplemented with (d7)d18:1 in the presence or absence 
of FB1 (35µM).  (d7)d18:2 formation was reduced but still detectable in presence of FB1, indicating 
that FADS3 can also metabolize the free LCB. F FADS3 in-vitro activity with the free LCB ((d7) d18:1) 
and the N-acylated form (d18:1/6:0). The free and the N-acylated form were both rapidly converted into 
(d7)d18:2 and d18:2/6:0, respectively.  Data shown as mean±SD, n=3, paired t-test, ***P < 0.001; ****P 

























































Fig 3. FADS3 is required for Δ14 LCB desaturation.  
A HeLa cells were transfected with hFADS3 siRNA (siFADS3) or scrambled control siRNA (siSCR). 
The silencing of hFADS3 was confirmed by western blot with a polyclonal antibody against FADS3. 
Calnexin was used as a loading control (n=3). B-D Sphingoid base profiling of cells and plasma.  B 
HeLa cells were transfected with siSCR and siFADS3 for 72 hours and subsequently cultured for 24 
hours in the presence of 2 µM (d7)d18:0 and (d3)m18:0. The formation of (d7)d18:2 was significantly 
decreased in the siFADS3 treated cells. No difference was seen for the precursors (d7)d18:0 and 
(d7)d18:1. C The conversion of (d3)m18:0 into (d3)m18:1 was also reduced in siFADS3 treated cells 
compared to controls (siSCR). Data shown as mean±SD, unpaired t-test, *P < 0.05, ***P < 0.001 D 
d18:2 was absent in plasma of the two FADS (-/-) mice (M1/M2), and about 50% in the FADS (+/-) 
mice compared to WT. Total d18:1 levels were not different. E WT and FADS3 overexpressing 
HEK293 cells were plated at low density (150 000 cells/well of 24 well plate) and supplemented with 
increasing concentrations of m18:0 (0-1.5 µM). After 48 hours, the number of attached cells was 
significantly higher in FADS3 overexpressing cells than in WT. Data shown as mean ±SD (n=3) and 
compared by two-way ANOVA with Bonferroni`s correction *<0.05, **P < 0.01, ***P < 0.001. F 
Interplay between the two LCB desaturases DEGS1 and FADS3. DEGS1 introduces the Δ4E DB into 
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